SGLT2 Inhibitors and Cirrhosis: A Unique Perspective on the Comanagement of Diabetes Mellitus and Ascites

Overview

Journal Clin Liver Dis (Hoboken)

Specialty Gastroenterology

Date 2019 Apr 18

PMID 30992805

Citations 20

Authors

Saad Saffo

Tamar Taddei

Affiliations

Soon will be listed here.

Citing Articles

Safety and Efficacy of Dapagliflozin in Recurrent Ascites: A Pilot Study.

Singh V, De A, Aggrawal R, Singh A, Charak S, Bhagat N Dig Dis Sci. 2024; 70(2):835-842.

PMID: 39384712 DOI: 10.1007/s10620-024-08667-4.

Pharmacological Interventions for Cirrhotic Ascites: From Challenges to Emerging Therapeutic Horizons.

Gao Y, Liu X, Gao Y, Duan M, Hou B, Chen Y Gut Liver. 2024; 18(6):934-948.

PMID: 39205495 PMC: 11565010. DOI: 10.5009/gnl240038.

Clinical Presentation, Pathological Spectrum, and Outcomes of Alcoholic Cirrhosis-Related Immunoglobulin A Nephropathy.

Ronsin C, Braud P, Kandel-Aznar C, Dujardin A, Petit C, Larmet D Kidney Int Rep. 2024; 9(5):1369-1378.

PMID: 38707818 PMC: 11069013. DOI: 10.1016/j.ekir.2024.02.1397.

From liver to hormones: The endocrine consequences of cirrhosis.

Quiroz-Aldave J, Gamarra-Osorio E, Durand-Vasquez M, Rafael-Robles L, Gonzales-Yovera J, Quispe-Flores M World J Gastroenterol. 2024; 30(9):1073-1095.

PMID: 38577191 PMC: 10989500. DOI: 10.3748/wjg.v30.i9.1073.

Reduced mortality and morbidity associated with metformin and SGLT2 inhibitor therapy in patients with type 2 diabetes mellitus and cirrhosis.

Huynh D, Renelus B, Jamorabo D BMC Gastroenterol. 2023; 23(1):450.

PMID: 38114915 PMC: 10731715. DOI: 10.1186/s12876-023-03085-8.

References

Vlachogiannakos J, Tang A, Patch D, Burroughs A . Angiotensin converting enzyme inhibitors and angiotensin II antagonists as therapy in chronic liver disease. Gut. 2001; 49(2):303-8. PMC: 1728379. DOI: 10.1136/gut.49.2.303. View

Kasichayanula S, Liu X, Zhang W, Pfister M, LaCreta F, Boulton D . Influence of hepatic impairment on the pharmacokinetics and safety profile of dapagliflozin: an open-label, parallel-group, single-dose study. Clin Ther. 2011; 33(11):1798-808. DOI: 10.1016/j.clinthera.2011.09.011. View

Heise T, Seewaldt-Becker E, Macha S, Hantel S, Pinnetti S, Seman L . Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks' treatment with empagliflozin once daily in patients with type 2 diabetes. Diabetes Obes Metab. 2013; 15(7):613-21. DOI: 10.1111/dom.12073. View

Ge P, Runyon B . The changing role of beta-blocker therapy in patients with cirrhosis. J Hepatol. 2013; 60(3):643-53. DOI: 10.1016/j.jhep.2013.09.016. View

Malaguarnera R, Belfiore A . The emerging role of insulin and insulin-like growth factor signaling in cancer stem cells. Front Endocrinol (Lausanne). 2014; 5:10. PMC: 3912738. DOI: 10.3389/fendo.2014.00010. View

Zhang X, Harmsen W, Mettler T, Kim W, Roberts R, Therneau T . Continuation of metformin use after a diagnosis of cirrhosis significantly improves survival of patients with diabetes. Hepatology. 2014; 60(6):2008-16. PMC: 4218882. DOI: 10.1002/hep.27199. View

Ptaszynska A, Johnsson K, Parikh S, de Bruin T, Apanovitch A, List J . Safety profile of dapagliflozin for type 2 diabetes: pooled analysis of clinical studies for overall safety and rare events. Drug Saf. 2014; 37(10):815-29. DOI: 10.1007/s40264-014-0213-4. View

Vallon V . The mechanisms and therapeutic potential of SGLT2 inhibitors in diabetes mellitus. Annu Rev Med. 2014; 66:255-70. DOI: 10.1146/annurev-med-051013-110046. View

Garcia-Compean D, Gonzalez-Gonzalez J, Lavalle-Gonzalez F, Gonzalez-Moreno E, Maldonado-Garza H, Villarreal-Perez J . The treatment of diabetes mellitus of patients with chronic liver disease. Ann Hepatol. 2015; 14(6):780-8. DOI: 10.5604/16652681.1171746. View

10.

Fitchett D, Zinman B, Wanner C, Lachin J, Hantel S, Salsali A . Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial. Eur Heart J. 2016; 37(19):1526-34. PMC: 4872285. DOI: 10.1093/eurheartj/ehv728. View

11.

Heerspink H, Perkins B, Fitchett D, Husain M, Cherney D . Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications. Circulation. 2016; 134(10):752-72. DOI: 10.1161/CIRCULATIONAHA.116.021887. View

12.

Gines P, Arroyo V, Quintero E, Planas R, Bory F, Cabrera J . Comparison of paracentesis and diuretics in the treatment of cirrhotics with tense ascites. Results of a randomized study. Gastroenterology. 1987; 93(2):234-41. DOI: 10.1016/0016-5085(87)91007-9. View

13.

Gines P, Quintero E, Arroyo V, Teres J, Bruguera M, Rimola A . Compensated cirrhosis: natural history and prognostic factors. Hepatology. 1987; 7(1):122-8. DOI: 10.1002/hep.1840070124. View